Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mysimba added to Back on Track for weight regain after bariatric surgery
NL-OMON54284Recruiting
- Sponsor
- Zuyderland
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of naltrexone + bupropion in obesity (3 arms), sponsored by Zuyderland. Primary endpoint: Successful weight loss at 22 weeks. Started Mar 2023; status: recruiting.
02
Drugs
naltrexone + bupropion
03
Conditions
obesity
Beyond the preview
Go deeper on NL-OMON54284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54284.